We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.36B
1-Year Est. Return 204.53%
This Fund
S&P 500
This Quarter Est. Return
+43.68%
1 Year Est. Return
+204.53%
3 Year Est. Return
+306.25%
5 Year Est. Return
+490.45%
10 Year Est. Return
+14,115.48%
AUM
$1.35B
AUM Growth
+$397M
Cap. Flow
+$127M
Cap. Flow %
9.41%
Top 10 Hldgs %
60.29%
Holding
72
New
21
Increased
13
Reduced
7
Closed
23

Top Buys

Rank Stock Value
1
ORIC icon
Oric Pharmaceuticals
ORIC
+$84.3M
2
XNCR icon
Xencor
XNCR
+$62.7M
3
RNAM
Avidity Biosciences
RNAM
+$60.7M
4
AKUS
Akouos Inc
AKUS
+$44M
5
RCUS icon
Arcus Biosciences
RCUS
+$41M

Top Sells

Rank Stock Value
1
ARVN icon
Arvinas
ARVN
+$61.6M
2
FATE icon
Fate Therapeutics
FATE
+$51.3M
3
IRWD icon
Ironwood Pharmaceuticals
IRWD
+$45M
4
KYNB
Kyntra Bio
KYNB
+$30.7M
5
IPHA
Innate Pharma
IPHA
+$29.8M

Sector Composition

Rank Sector Weight
1 Healthcare 92.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
STRO icon
26
Sutro Biopharma
STRO
$374M
$14.2M 1.05%
+182,849
New +$17.5M
CNST
27
CALL
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$12M 0.89%
+400,000
New +$14.4M
RLMD icon
28
Relmada Therapeutics
RLMD
$525M
$8.95M 0.66%
+200,000
New +$8.46M
KROS icon
29
Keros Therapeutics
KROS
$210M
$8.26M 0.61%
+220,216
New +$6.78M
CBIO
30
Crescent Biopharma
CBIO
$537M
$7.1M 0.52%
+18,890
New +$5.35M
ACAD icon
31
Acadia Pharmaceuticals
ACAD
$4.3B
$6.56M 0.48%
135,413
-188,476
-58% -$9.05M
EVLO
32
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$6.13M 0.45%
+62,500
New +$5.47M
PRVL
33
DELISTED
Prevail Therapeutics Inc. Common Stock
PRVL
$5.47M 0.4%
367,218
-1,881,088
-84% -$29M
IRWD icon
34
CALL
Ironwood Pharmaceuticals
IRWD
$634M
$5.16M 0.38%
+500,000
New +$5.12M
XCUR icon
35
Exicure
XCUR
$12M
$4.08M 0.3%
11,155
-7,787
-41% -$2.82M
SVRA icon
36
Savara
SVRA
$1.13B
$3.57M 0.26%
1,432,664
– –
DNTH icon
37
Dianthus Therapeutics
DNTH
$5.52B
$3.38M 0.25%
+28,125
New +$3.96M
LSACU
38
DELISTED
LifeSci Acquisition Corp. Unit 1 COM & 1 WT
LSACU
$3.3M 0.24%
300,000
– –
ACRS icon
39
Aclaris Therapeutics
ACRS
$778M
$2.48M 0.18%
1,531,312
-556,000
-27% -$745K
RPRX icon
40
Royalty Pharma
RPRX
$25.4B
$2.43M 0.18%
+50,000
New +$2.47M
FPRX
41
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$2.32M 0.17%
379,945
+123,870
+48% +$510K
CRVS icon
42
Corvus Pharmaceuticals
CRVS
$1.19B
$2.01M 0.15%
737,612
– –
RPTX
43
DELISTED
Repare Therapeutics
RPTX
$1.55M 0.11%
+50,000
New +$1.61M
ICPT
44
CALL
DELISTED
Intercept Pharmaceuticals, Inc.
ICPT
$1.21M 0.09%
+25,300
New +$1.95M
MGTX icon
45
MeiraGTx Holdings
MGTX
$1.13B
$1.19M 0.09%
94,819
– –
XOMA
46
DELISTED
Xoma
XOMA
$1M 0.07%
50,809
– –
KLDO
47
DELISTED
Kaleido Biosciences, Inc. Common Stock
KLDO
$233K 0.02%
+31,374
New +$210K
EQ icon
48
Equillium
EQ
$156M
$174K 0.01%
+59,014
New +$168K
PLRX icon
49
Pliant Therapeutics
PLRX
$66.3M
$42K ﹤0.01%
+1,300
New +$34.5K
ARVN icon
50
Arvinas
ARVN
$517M
– –
-1,528,031
Closed -$61.6M
1
2
3

Similar funds

HFM
Harvest Fund Management Beijing, China $2.35B AUM 49.85% 1-Year Est. Return
CC
Capital Counsel New York $2.35B AUM 21.34% 1-Year Est. Return
CPC
Cookson Peirce & Co Pittsburgh, Pennsylvania $2.36B AUM 68.36% 1-Year Est. Return
SCA
STALEY CAPITAL ADVISERS Pittsburgh, Pennsylvania $2.36B AUM 23.72% 1-Year Est. Return
ROIC
Route One Investment Company San Francisco, California $2.35B AUM 11.7% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $2.37B AUM 16.36% 1-Year Est. Return
G
GenTrust Miami, Florida $2.34B AUM 18.43% 1-Year Est. Return
MC
Moors & Cabot Boston, Massachusetts $2.34B AUM 30.42% 1-Year Est. Return

EcoR1 Capital's Q2 2020 Portfolio in Review

As of Q2 2020, EcoR1 Capital held 72 positions worth $1.35B, up 41% from $957M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

EcoR1 Capital deployed $127M of net new capital in Q2 2020, opening 21 new positions and adding to 13 existing holdings. Its largest new stake was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, down from 92% a quarter earlier.

On the sell side, the largest reduction was Fate Therapeutics, an estimated $51.3M trimmed.

  • EcoR1 Capital's largest Q2 2020 buy was Oric Pharmaceuticals: 2,642,218 shares worth $89.1M.
  • EcoR1 Capital added most to Xencor in Q2 2020, an estimated $62.7M increase.
  • EcoR1 Capital's biggest Q2 2020 reduction was Fate Therapeutics, cutting an estimated $51.3M.
  • EcoR1 Capital fully exited Arvinas in Q2 2020, selling an estimated $61.6M.
  • EcoR1 Capital's ten largest holdings make up 60% of its $1.35B portfolio in Q2 2020.
  • EcoR1 Capital opened 21 new positions and closed 23 in Q2 2020.
  • EcoR1 Capital's portfolio value rose 41% quarter-over-quarter to $1.35B.

Based on EcoR1 Capital's 13F filing for Q2 2020, filed 14 Aug 2020.